Sysmex Stock Earnings Reports

Sysmex reported a meaningful YoY decline in Q1 FY2026 revenue and profit driven by two one-time, non-operational factors and a softer operating environment in China. The main one-time impacts were: (1) a deliberate restriction of order intake during the July global go-live of a new core internal system (SCM/production/logistics), which caused a JPY3.3 billion revenue shortfall and ~JPY3.0 billion operating profit impact (amortization of the new system also increased costs); and (2) a JPY1.7 billion cost-of-sales adjustment from a reassessment of overseas inventory valuations. Excluding these items, performance was broadly stable or growing on a local currency basis across most regions (Americas, EMEA, AP), while Japan and China were the primary areas of weakness. China faced a 5% local-currency revenue decline in Q1 attributable to intensified government medical cost-control measures (VBP, bundled-test restrictions such as CRP), and management now factors a 5–10% downside risk in China for H1. Management revised its H1 forecast (now expecting H1 revenue of JPY240 billion, down JPY12.5 billion, and H1 operating profit to JPY36 billion, down JPY8.5 billion) but maintained its full-year targets, citing expected recoveries from product launches (XR and CN series in the U.S.), progress in Alzheimer’s testing (amyloid-beta, ApoE, p-tau assays), medical robotics ramp (targeting ~100 robots this year and >10,000 procedures to date), and other regional initiatives (local production in India, Brazil expansion). Other notable items: U.S. reciprocal tariffs impact remains within prior guidance (JPY3–4 billion); SG&A rose due to direct-sales expansion and headcount; R&D spend declined YoY as some projects completed, but innovation investment continues. Management emphasizes these Q1 impacts are largely one-off and outlined measures to recover in H2, while also acknowledging communication on quarter-specific impacts could have been clearer.